Boditech Med Showcases Next-Gen Diagnostic Solutions at ADLM 2025, Expanding Presence in Americas
- Highlights include AFIAS automated immunoassay platform and key products like IGRA-TB and PENKID
- Launch of new veterinary POCT solutions including AFIAS-VET, VETCHROMA 3, UROCHROMA, and VETCHEMIS
- Strengthening market re-entry in North and South America through global partnerships and innovation
Boditech Med, a leading provider of point-of-care diagnostics, announced its participation in ADLM 2025 (Association for Diagnostics & Laboratory Medicine), held from July 29 to 31 in Chicago, USA.
As the largest diagnostics exhibition in North America, ADLM 2025 hosts more than 20,000 professionals and over 800 companies worldwide. This year’s event features more than 850 booths, along with keynote lectures and workshops addressing key healthcare issues such as AI integration, misinformation in medicine, genomics-based diagnostics, and environmental health impacts.
At the exhibition, Boditech Med is unveiling its AFIAS automated immunoassay platform alongside a comprehensive portfolio of innovative diagnostic solutions. Key highlights include:
• AFIAS IGRA-TB for rapid detection of latent tuberculosis
• PENKID for early prediction and monitoring of acute kidney injury
• TDM, HOMA-IR, and Vitamin D diagnostic kits for endocrine and metabolic assessments
In addition, the company is introducing its latest veterinary diagnostic lineup.
• AFIAS-VET and VETCHROMA 3 support immunoassays for animal diagnostics with automated and manual options to meet diverse on-site testing needs.
• UROCHROMA provides rapid urine analysis, and VETCHEMIS enables blood chemistry testing using whole blood samples—expanding the potential for point-of-care use in veterinary settings.
Through its presence at ADLM 2025, Boditech Med aims to accelerate global market expansion, with a renewed focus on reestablishing its footprint across North and South America. While sales in the Americas saw exceptional growth during the pandemic followed by a period of adjustment, the company is positioning 2025 as a turning point for renewed growth, backed by a strong sales network and expanded partnerships.
Eui-yeol Choi, CEO of Boditech Med, stated:
“ADLM 2025 presents a key opportunity to introduce our cutting-edge diagnostic technologies to the North American and Latin American markets. We are also unveiling our new veterinary diagnostic solutions to broaden our global reach.”
He added, “To further strengthen our regional partnerships, we are hosting the 3rd Latin America Distributor Conference on the eve of the exhibition.”